Comprehensive Guide to Hydralazine: Uses, Dosage, Side Effects, and More
What is Hydralazine?
Overview of Hydralazine
Generic Name: Hydralazine
Brand Name: Apresoline, generics
Drug Group: Vasodilator (antihypertensive)
Commonly Used For
- Treat hypertension (high blood pressure).
- Manage heart failure in combination with other drugs.
- Control hypertensive emergencies.
Key Characteristics
Form: Oral tablets (10 mg, 25 mg, 50 mg, 100 mg), injectable (20 mg/mL) (detailed in Dosage section).
Mechanism: Direct relaxation of arteriolar smooth muscle, decreasing peripheral vascular resistance.
Approval: FDA-approved (1953 for Apresoline) and EMA-approved for hypertension.
Indications and Uses of Hydralazine
Hydralazine is indicated for a range of cardiovascular conditions, leveraging its vasodilatory effects:
Hypertension: Treats essential hypertension, lowering blood pressure, per cardiology guidelines, supported by clinical trials showing reduction in systolic and diastolic BP.
Heart Failure: Manages congestive heart failure, improving cardiac output when combined with isosorbide dinitrate, recommended in heart failure protocols with evidence of improved survival in African-American patients.
Hypertensive Emergencies: Controls acute high blood pressure crises, stabilizing hemodynamics, with emergency medicine data.
Preeclampsia/Eclampsia: Used off-label in pregnancy to manage severe hypertension, reducing maternal and fetal risks, per obstetric research.
Pulmonary Hypertension: Investigated off-label to reduce pulmonary arterial pressure, improving right ventricular function, with pulmonology evidence.
Chronic Kidney Disease (CKD) Hypertension: Managed off-label to control blood pressure in CKD, protecting renal function, supported by nephrology studies.
Post-Operative Hypertension: Explored off-label to stabilize BP after major surgery, with anesthesiology data.
Resistant Hypertension: Used off-label in combination therapy for resistant hypertension, enhancing control, with hypertension management research.
Raynaud’s Phenomenon: Investigated off-label to improve peripheral circulation, reducing vasospasms, with vascular medicine studies.
Hypertensive Retinopathy: Managed off-label to reduce retinal damage from high BP, with ophthalmology evidence.
Dosage of Hydralazine
Dosage for Adults
Hypertension:
- Oral: Initial 10 mg 4 times daily, titrated to 25–50 mg 4 times daily, maximum 300 mg/day.
- IV: 5–10 mg every 20–30 minutes for emergencies, maximum 40 mg.
Heart Failure:
- Oral: Initial 37.5 mg 3 times daily, titrated to 75–225 mg/day with isosorbide dinitrate.
Hypertensive Emergencies:
- IV: 10–20 mg every 4–6 hours, adjusted for BP response.
Dosage for Children (≥1 month)
Hypertension:
- Oral: 0.75–1 mg/kg/day divided 4 times, maximum 7.5 mg/kg/day or 200 mg/day.
- IV: 0.1–0.2 mg/kg every 4–6 hours, under pediatric supervision.
Dosage for Pregnant Women
Pregnancy Category C: Use with caution for preeclampsia; oral 10–50 mg every 6 hours, consult an obstetrician.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).
Hepatic Impairment:
Mild to moderate (Child-Pugh A or B): Use cautiously; severe (Child-Pugh C): Avoid due to metabolism issues.
Concomitant Medications: Adjust if combined with beta-blockers (e.g., metoprolol), increasing hypotension risk.
Elderly: Start with 10 mg 2–3 times daily; titrate slowly.
Lupus-Like Syndrome: Discontinue if ANA positive with symptoms.
Additional Considerations
- Take this active ingredient with food to reduce GI upset, using a full glass of water.
- Monitor BP and heart rate during IV administration to prevent hypotension.
How to Use Hydralazine
Administration:
Oral: Swallow tablets whole with water or milk, taken with meals to minimize nausea.
IV: Administer slowly (over 1–2 minutes) by a healthcare provider to avoid rapid BP drop.
Timing: Use 2–4 times daily for oral, as prescribed for IV emergencies.
Monitoring: Watch for headache, palpitations, or signs of lupus (e.g., joint pain); report changes.
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from moisture and light.
- Keep out of reach of children due to overdose risk.
- Report severe dizziness, chest pain, or signs of allergic reactions immediately.
Contraindications for Hydralazine
Hypersensitivity: Patients with a known allergy to Hydralazine or vasodilators.
Mitral Valve Rheumatic Heart Disease: Contraindicated due to increased pulmonary hypertension risk.
Coronary Artery Disease: Avoid in acute coronary syndrome due to reflex tachycardia.
Idiopathic Systemic Lupus Erythematosus (SLE): Contraindicated due to lupus-like syndrome exacerbation.
Severe Tachycardia: Avoid in uncontrolled heart rate conditions.
Warnings & Precautions for Hydralazine
General Warnings
Hypotension: Risk of orthostatic hypotension; monitor BP after dosing.
Lupus-Like Syndrome: Risk of drug-induced lupus with long-term use; check ANA levels.
Reflex Tachycardia: Risk of palpitations; use with beta-blockers.
Peripheral Neuritis: Risk of nerve damage; supplement with vitamin B6.
Hematologic Effects: Rare blood dyscrasias; monitor CBC.
Additional Warnings
Cardiac Ischemia: Risk in patients with CAD; assess chest pain.
Hepatic Toxicity: Rare liver injury; monitor liver enzymes.
Renal Impairment: Risk of accumulation; adjust dose.
Pulmonary Hypertension: Risk in mitral valve disease; avoid.
Hypersensitivity Reactions: Rare anaphylaxis; discontinue if severe.
Use in Specific Populations
Pregnancy: Category C; use with caution and monitoring.
Breastfeeding: Use caution; monitor infant for effects.
Elderly: Higher risk of hypotension; start low.
Children: Safe for hypertension with supervision.
Renal/Hepatic Impairment: Adjust or avoid in severe cases.
Additional Precautions
- Inform your doctor about heart disease, lupus, or long-term medication use before starting this medication.
- Avoid sudden position changes to prevent dizziness.
Overdose and Management of Hydralazine
Overdose Symptoms
Hypotension, dizziness, or syncope.
Severe cases: Shock, tachycardia, or myocardial ischemia.
Headache, nausea, or flushing as early signs.
Coma or profound bradycardia with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer IV fluids, vasopressors (e.g., norepinephrine), and monitor vital signs.
Specific Treatment: No specific antidote; manage hypotension and support cardiac function.
Monitor: Check BP, heart rate, and ECG for 24–48 hours.
Additional Notes
- Overdose risk is moderate; store securely and limit access.
- Report persistent symptoms (e.g., severe headache, chest pain) promptly.
Side Effects of Hydralazine
Common Side Effects
- Headache (20–30%, relieved with analgesics)
- Palpitations (15–25%, decreases with beta-blockers)
- Nausea (10–20%, managed with food)
- Dizziness (10–15%, reduced with slow position changes)
- Flushing (5–10%, transient)
These effects may subside with adaptation.
Serious Side Effects
Seek immediate medical attention for:
- Autoimmune: Drug-induced lupus (joint pain, rash).
- Cardiac: Tachycardia or angina.
- Neurological: Peripheral neuritis or confusion.
- Hematologic: Hemolytic anemia or leukopenia.
- Allergic: Rash, angioedema, or anaphylaxis.
Additional Notes
- Regular monitoring for lupus symptoms, blood counts, and cardiac function is advised.
- Report any unusual symptoms (e.g., persistent headache, joint pain) immediately to a healthcare provider.
Drug Interactions with Hydralazine
This active ingredient may interact with:
- Beta-Blockers: Enhances hypotension (e.g., metoprolol); monitor BP.
- Diuretics: Potentiates hypotensive effects; adjust dose.
- ACE Inhibitors: Increases renal impairment risk; monitor kidney function.
- NSAIDs: Reduces antihypertensive efficacy; use cautiously.
- Lithium: Alters levels; monitor.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this vasodilator as prescribed for hypertension or heart failure, following the daily schedule.
Monitoring: Report headache, palpitations, or signs of lupus immediately.
Lifestyle: Avoid salt-rich foods; maintain regular exercise.
Diet: Take with food to reduce nausea; avoid high-potassium if at risk.
Emergency Awareness: Know signs of hypotension or lupus; seek care if present.
Follow-Up: Schedule regular check-ups every 1–3 months to monitor BP, ANA levels, and cardiac health.
Pharmacokinetics of Hydralazine
Absorption: Oral, peak at 1–2 hours; bioavailability ~10–26% (first-pass effect).
Distribution: Volume of distribution ~0.5 L/kg; 87% protein-bound.
Metabolism: Hepatic via acetylation to inactive metabolites; half-life 3–7 hours.
Excretion: Primarily renal (60–70% as metabolites); fecal (10%).
Half-Life: 3–7 hours, with prolonged effects in slow acetylators.
Pharmacodynamics of Hydralazine
This drug exerts its effects by:
Relaxing arteriolar smooth muscle, reducing peripheral resistance and blood pressure.
Triggering reflex tachycardia, which can be mitigated with beta-blockers.
Providing cardioprotective effects in heart failure by reducing afterload.
Exhibiting dose-dependent risks of lupus-like syndrome and hypotension.
Storage of Hydralazine
Temperature: Store at 20–25°C (68–77°F); protect from light and moisture.
Protection: Keep in original container, away from heat and humidity.
Safety: Store in a secure location out of reach of children and pets due to overdose potential.
Disposal: Dispose of unused tablets or injectable vials per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Hydralazine treat?
A: This medication treats hypertension and heart failure.
Q: Can this active ingredient cause headache?
A: Yes, headache is common; report if severe.
Q: Is Hydralazine safe for children?
A: Yes, for hypertension with supervision.
Q: How is this drug taken?
A: Orally or IV, as directed.
Q: How long is Hydralazine treatment?
A: Often long-term, with monitoring.
Q: Can I use Hydralazine if pregnant?
A: Yes, with caution; consult a doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1953 (Apresoline) for hypertension.
European Medicines Agency (EMA): Approved for hypertension and heart failure.
Other Agencies: Approved globally for cardiovascular therapy; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Apresoline (Hydralazine) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Hydralazine Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Hydralazine: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Hydralazine.
- WHO’s inclusion of Hydralazine for hypertension.
- Journal of Hypertension. (2022). Hydralazine in Resistant Hypertension.
- Peer-reviewed article on Hydralazine efficacy (note: access may require a subscription).
